Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990753 | PMC |
| http://dx.doi.org/10.1172/jci.insight.169136 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Breathing down resistance: Tackling hypoxia to overcome immunotherapy barriers in lung cancer.
J Exp Med
January 2025
The Pritzker School of Molecular Engineering, Cummings Life Science Center, The University of Chicago, Chicago, IL, USA.
In this issue of JEM, Robles-Oteiza et al. (https://doi.org/10.
View Article and Find Full Text PDFPathophysiology-Driven Approaches for Overcoming Nanomedicine Resistance in Pancreatic Cancer.
Mol Pharm
December 2024
Department of Endocrinology, Amrita Institute of Medical Sciences and Research Centre, AIMS Health Sciences Campus, Amrita Vishwa Vidyapeetham, Kochi, Kerala 682041, India.
Article Synopsis
- * CRNMs utilize advanced biomaterials to achieve controlled release and stimuli sensitivity, specifically designed to address drug resistance in PDAC, while also considering pharmacokinetics and RNA interference for better therapeutic outcomes.
- * The review emphasizes the shortcomings of current animal models in accurately reflecting PDAC complexities and discusses past clinical failures, highlighting the potential of CRNMs to target critical pathways like Notch and Hedgehog for improved treatment strategies.
Pharmacologic ascorbate induces transient hypoxia sensitizing pancreatic ductal adenocarcinoma to a hypoxia activated prodrug.
Free Radic Biol Med
September 2024
Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Hypoxic tumor microenvironments pose a significant challenge in cancer treatment. Hypoxia-activated prodrugs like evofosfamide aim to specifically target and eliminate these resistant cells. However, their effectiveness is often limited by reoxygenation after cell death.
View Article and Find Full Text PDF[F]FMISO-PET imaging reveals the role of hypoxia severity in checkpoint blockade response.
Nucl Med Biol
June 2024
Department of Radiology, The University of Alabama at Birmingham, Birmingham, AL, United States of America; O'Neal Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, AL, United States of America. Electronic address:
Context: Hypoxia within the tumor microenvironment is a critical factor influencing the efficacy of immunotherapy, including immune checkpoint inhibition. Insufficient oxygen supply, characteristic of hypoxia, has been recognized as a central determinant in the progression of various cancers. The reemergence of evofosfamide, a hypoxia-activated prodrug, as a potential treatment strategy has sparked interest in addressing the role of hypoxia in immunotherapy response.
View Article and Find Full Text PDFHypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma.
Int J Biol Sci
March 2024
Department of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China.
Article Synopsis
- Hypoxia contributes to the development of hepatocellular carcinoma (HCC) but also presents opportunities for treatment using hypoxia-activated prodrugs (HAPs), like TH-302.* -
- The study focuses on creating a hypoxia-activated antibody (HAP103) targeting a specific form of pyruvate kinase (PKM2) to improve treatment effectiveness and reduce side effects compared to traditional antibodies.* -
- HAP103 demonstrated selective targeting and significant tumor-inhibitory activity in HCC mouse models, showing potential for synergistic effects with TH-302 while minimizing toxicity, making it a promising advancement in targeted cancer therapy.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!